

# Real-World Impact of Bimekizumab on Disease Activity in axial spondyloarthritis patients including the EARLY subpopulation (EXPEDITE)

**First published:** 30/04/2025

**Last updated:** 03/06/2025

Study

Ongoing

## Administrative details

### EU PAS number

EUPAS1000000519

---

### Study ID

1000000519

---

### DARWIN EU® study

No

---

### Study countries

- Austria
- Belgium
- European Union

- France
  - Germany
  - Greece
  - Italy
  - Netherlands
  - Poland
  - Spain
  - Switzerland
  - United Kingdom
- 

### **Study status**

Ongoing

## Contact details

### **Study institution contact**

UCB Cares [UCBCares.global@ucb.com](mailto:UCBCares.global@ucb.com)

**Study contact**

[UCBCares.global@ucb.com](mailto:UCBCares.global@ucb.com)

### **Primary lead investigator**

UCB Cares

**Primary lead investigator**

## Study timelines

### **Date when funding contract was signed**

Planned: 01/04/2025

Actual: 09/04/2025

---

### **Study start date**

Planned: 30/05/2025

Actual: 21/05/2025

---

### **Date of final study report**

Planned: 25/10/2027

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

UCB Biopharma SRL

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Other study registration identification numbers and links

Internal study ID: SPA002

## Methodological aspects

### Study type

**Study topic:**

Human medicinal product

---

**Study type:**

Non-interventional study

---

## Study drug and medical condition

**Medicinal product name**

BIMZELX

---

**Study drug International non-proprietary name (INN) or common name**

BIMEKIZUMAB

---

**Anatomical Therapeutic Chemical (ATC) code**

(L04AC21) bimekizumab

bimekizumab

---

**Medical condition to be studied**

Axial spondyloarthritis

Data management

ENCePP Seal

---

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Use of a Common Data Model (CDM)

### **CDM mapping**

No

## Data quality specifications

### **Check conformance**

Yes

---

### **Check completeness**

Yes

---

### **Check stability**

Yes

---

### **Check logical consistency**

Yes

## Data characterisation

### **Data characterisation conducted**

No